In Response to: "Comparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?"
暂无分享,去创建一个
N. Myall | H. Wakelee | D. Camidge | S. Braunstein | E. Pollom | C. Rusthoven | C. McCoach | T. Patil | S. Nagpal | F. Sun | Nicholas J. Thomas | S. Sinha | R. Mushtaq | Chandler Yu